The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.

Hepatology International
Akito NozakiKTK49 Liver Study Group

Abstract

Direct-acting anti-virals (DAAs) have markedly improved the effectiveness of anti-viral therapy for chronic hepatitis C (CHC) patients. In a phase III trial in Japan, treatment with the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir (G/P) resulted in a small number of patients with refractory factors. We aimed to evaluate the effectiveness and safety of G/P, especially among patients with these refractory factors, and the influence of these factors on treatment. In a prospective, multicenter study involving 33 medical institutions, 1439 patients were treated with G/P, and their efficacy, safety, and most frequent adverse effects (AEs) were analyzed. Overall SVR12 rates were 99.1% (1397/1410) in the per-protocol-analysis, and genotype sustained virologic response SVR12 rates were: genotype 1, 99.4% (707/711); genotype 2, 99.4% (670/674); genotype 3, 80.0% (16/20). DAA-naïve patients (p = 0.008) with HCV genotype except 3 (genotype 1 vs. 3, p = 2.68 × 10-5; genotype 2 vs. 3, p = 3.28 × 10-5) had significantly higher SVR12 rates. No significant difference was observed between CKD stage 1-3 (99.1% [1209/1220]) and chronic kidney disease (CKD) stage 4-5 (98.9% [188/190]) patients, or between cirrhotic (99....Continue Reading

References

Jun 15, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anaïs Vallet-PichardStanislas Pol
Apr 3, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Seiichi MatsuoUNKNOWN Collaborators developing the Japanese equation for estimated GFR
Jan 24, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David R NelsonUNKNOWN ALLY-3 Study Team
Feb 9, 2017·Liver International : Official Journal of the International Association for the Study of the Liver·Christophe HézodeJean-Pierre Bronowicki
Feb 15, 2017·Antimicrobial Agents and Chemotherapy·Teresa I NgChristine Collins
May 1, 2017·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Masanori AtsukawaKatsuhiko Iwakiri
May 14, 2017·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Masanori AtsukawaKatsuhiko Iwakiri
Jun 1, 2017·The New England Journal of Medicine·Marc BourlièreUNKNOWN POLARIS-1 and POLARIS-4 Investigators
Sep 3, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hidenori ToyodaHiromitsu Kumada
Sep 20, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David WylesFederico J Mensa
Sep 28, 2017·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Tarik AsselahFederico J Mensa
Oct 12, 2017·The New England Journal of Medicine·Edward GaneFederico J Mensa
Nov 21, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Fred PoordadFederico J Mensa
Dec 23, 2017·International Journal of Molecular Sciences·Kyoko Tsukiyama-Kohara, Michinori Kohara
Jan 25, 2018·The New England Journal of Medicine·Stefan ZeuzemFederico J Mensa
Feb 10, 2018·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David SmithUNKNOWN STOP-HCV Consortium
Apr 14, 2018·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Nov 26, 2018·Journal of Hepatology·Roberta D'AmbrosioUNKNOWN NAVIGATORE-Lombardia Study Group
Mar 9, 2019·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Eiichi OgawaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group
Apr 9, 2019·Journal of Hepatology·Giuseppe CabibboUNKNOWN Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group
Apr 10, 2019·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Sanne Brun JensenJudith Margarete Gottwein
Jul 20, 2019·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Akihiro TamoriNorifumi Kawada

❮ Previous
Next ❯

Citations

Oct 22, 2020·Journal of Clinical and Translational Hepatology·Hong-Qin XuYan-Hang Gao
Feb 20, 2021·Journal of Clinical and Translational Hepatology·Xiaoqing Liu, Peng Hu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.